Hoth Therapeutics Announces Preclinical Results For HT-ALZ In Alsheimer's Disease, Showing 'Positive Effects on Cognitive Function'
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics announced positive preclinical results for its HT-ALZ treatment in Alzheimer's disease, showing improvements in cognitive function. The company's stock, HOTH, may be impacted by this news.
June 06, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hoth Therapeutics' HT-ALZ treatment showed positive effects on cognitive function in Alzheimer's disease during preclinical trials.
The positive preclinical results for Hoth Therapeutics' HT-ALZ treatment in Alzheimer's disease indicate potential for the treatment's success in future clinical trials. This news may lead to increased investor interest and a potential short-term increase in HOTH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100